Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/d50ddc69-3da5-4069-b52c-375cde0fc19c/gr2_lrg.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
![A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health](https://www.thelancet.com/cms/asset/0fbe43e7-b69c-43d2-bff9-10ce650542f3/gr1.jpg)
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
![Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - ScienceDirect Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168827822031117-ga1.jpg)
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - ScienceDirect
![Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data](https://www.archivesofmedicalscience.com/f/pictures/99749_28bf0.jpg)
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
![Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial - Kiyota - 2022 - Cancer - Wiley Online Library Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial - Kiyota - 2022 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ea8bc1f-ec67-4b1d-a1b6-7f66a1419417/cncr34181-fig-0001-m.jpg)
Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial - Kiyota - 2022 - Cancer - Wiley Online Library
![Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914008727-fx1.jpg)
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
![Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/480689df-d7d2-4224-9823-835cc1312b92/gr1.jpg)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
![Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer | Breast Cancer Research | Full Text Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer | Breast Cancer Research | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-019-1201-5/MediaObjects/13058_2019_1201_Fig1_HTML.png)
Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer | Breast Cancer Research | Full Text
![Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/341170479/figure/fig2/AS:962781394255883@1606556380401/Kaplan-Meier-curves-for-overall-survival-The-median-overall-survival-was-180months-95.png)
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram
![Cancers | Free Full-Text | Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients Cancers | Free Full-Text | Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients](https://www.mdpi.com/cancers/cancers-11-01890/article_deploy/html/images/cancers-11-01890-g001.png)
Cancers | Free Full-Text | Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients
![562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer 562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/31/Suppl_3/A251.2/F1.large.jpg)